Wave Life Sciences (WVE) Non-Current Deffered Revenue (2016 - 2026)
Wave Life Sciences (WVE) posted Non-Current Deffered Revenue of $14.6 million for Q1 2026, up 87.18% on a QoQ basis from $7.8 million in Q4 2025, and up 161.39% year-over-year from $5.6 million in Q1 2025.
Wave Life Sciences (WVE) Non-Current Deffered Revenue (2016 - 2026) Analysis & Trends
Wave Life Sciences' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $14.6 million for Q1 2026.
- Quarterly Non-Current Deffered Revenue rose 161.39% year-over-year to $14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (up 161.39% YoY) and the FY2025 annual result came in at $7.8 million, up 27.86% from the prior year.
- Non-Current Deffered Revenue was $14.6 million for Q1 2026 at Wave Life Sciences, up from $7.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $130.8 million in Q1 2023 and bottomed at $4.2 million in Q2 2025.
- A 5-year average of $44.6 million and a median of $15.6 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue slumped 90.83% — and 2026, when it surged 161.39%.
- Wave Life Sciences' Non-Current Deffered Revenue stood at $79.8 million in 2022, then tumbled by 80.44% to $15.6 million in 2023, then tumbled by 60.91% to $6.1 million in 2024, then rose by 27.86% to $7.8 million in 2025, then soared by 87.18% to $14.6 million in 2026.
- Business Quant data shows WVE's Non-Current Deffered Revenue at $14.6 million in Q1 2026, $7.8 million in Q4 2025, and $11.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Wave Life Sciences | 1.16 Bn | 612.38 Mn | - | 14.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.60 Mn |
| Dec 31, 2025 | 7.80 Mn |
| Sep 30, 2025 | 11.68 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 6.10 Mn |
| Sep 30, 2024 | 18.49 Mn |
| Jun 30, 2024 | 9.58 Mn |
| Mar 31, 2024 | 12.54 Mn |
| Dec 31, 2023 | 15.60 Mn |
| Sep 30, 2023 | 105.38 Mn |
| Jun 30, 2023 | 104.54 Mn |
| Mar 31, 2023 | 130.82 Mn |
| Dec 31, 2022 | 79.77 Mn |
| Sep 30, 2022 | 80.23 Mn |
| Jun 30, 2022 | 75.26 Mn |
| Mar 31, 2022 | 76.57 Mn |
| Dec 31, 2021 | 77.48 Mn |
| Sep 30, 2021 | 107.61 Mn |
| Jun 30, 2021 | 106.09 Mn |